Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants

Inclusion Criteria: * Women with venous thromboembolism * Age: 18 - 50 years * Regular menstrual bleeding * Treatment with DOACs for at least 7 days before inclusion * Full therapeutic anticoagulation with rivaroxaban 1 x 20 mg, apixaban 2 x 5 mg, edoxaban 60mg once daily or dabigatran 2 x 150mg for at least the next four months * Written informed consent Exclusion Criteria: * Hysterectomy or ovariectomy * Known heavy menstrual bleeding * Hormonal contraceptives * Hormone replacement therapy * Use of hormone releasing intrauterine System (IUS) * Contraindications to treatment with DOACs * Treatment with rivaroxaban 15 mg twice daily (first three weeks after diagnosis of venous thrombosis) or apixaban 10 mg twice daily (first week after diagnosis of venous thrombosis) * Treatment with rivaroxaban (10 mg or 15 mg once daily) or apixaban (2,5 mg twice daily) in reduced therapeutic dosages * Participation in any other trial